Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10504 and Midazolam DDI in NSCLC
NCT07685041Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2026
- Primary completion
- Nov 2026
01
Overview
Phase 1, open-label, single-arm trial of HS-10504 in non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Plasma Concentration at 24 hours, Area Under the Curve from Time Zero to Last Quantifiable Concentration at 24 hours and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
HS-10504
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07685041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07685041.